The relevance of non-human primate and rodent malaria models for humans by Langhorne, Jean et al.
COMMENTARY Open Access
The relevance of non-human primate and rodent
malaria models for humans
Jean Langhorne
1*, Pierre Buffet
2, Mary Galinski
3, Michael Good
4, John Harty
5, Didier Leroy
6, Maria M Mota
7,
Erica Pasini
8, Laurent Renia
9, Eleanor Riley
10, Monique Stins
11, Patrick Duffy
12
Abstract
At the 2010 Keystone Symposium on “Malaria: new approaches to understanding Host-Parasite interactions”,a n
extra scientific session to discuss animal models in malaria research was convened at the request of participants.
This was prompted by the concern of investigators that skepticism in the malaria community about the use and
relevance of animal models, particularly rodent models of severe malaria, has impacted on funding decisions and
publication of research using animal models. Several speakers took the opportunity to demonstrate the similarities
between findings in rodent models and human severe disease, as well as points of difference. The variety of
malaria presentations in the different experimental models parallels the wide diversity of human malaria disease
and, therefore, might be viewed as a strength. Many of the key features of human malaria can be replicated in a
variety of nonhuman primate models, which are very under-utilized. The importance of animal models in the
discovery of new anti-malarial drugs was emphasized. The major conclusions of the session were that experimental
and human studies should be more closely linked so that they inform each other, and that there should be wider
access to relevant clinical material.
Background
The 2010 Keystone symposium on malaria (Malaria:
New Approaches to Understanding Host-Parasite Inter-
actions), convened leading experts in malaria immunol-
ogy and pathogenesis to focus on new approaches for
understanding host-parasite interactions. Many of the
participating scientists conduct their research using
rodent or non-human primate experimental models,
which have been long-standing tools for malaria immu-
nology and pathogenesis research, basic discovery, drug
testing and vaccine development. The relevance of
experimental rodent malaria models has recently been a
contentious issue in the research community [1-6], and
individual participants expressed concern that scepticism
about the usefulness of these and other models
adversely impacts funding, publishing, critical training
opportunities, and the advancement of research. Based
on the scientific and practical importance of the topic,
the assembled scientists convened a special session to
discuss their views on the importance of model systems
as tools for understanding human malaria.
Discussion
Although the major focus of the ensuing discussion was
animal models, Nick Anstey (Menzies School of Public
Health, Darwin) pointed out that researchers have faced
similar challenges when seeking support to investigate
human malaria, which often entails studies of associa-
tion that cannot conclude causality. For this reason,
observational research on humans who naturally acquire
malaria is sometimes criticized as inconclusive, with the
consequence that funding and publication are impeded
in this area. Despite these criticisms, studies of malaria
in humans are clearly desirable, but many limitations,
such as the lack of access to relevant organs and tissue
samples, and the inability to manipulate the immune
response for mechanistic studies, mandate additional
approaches, where animal models may be most appro-
priate. Furthermore, all meaningful studies on human
malaria require appropriately documented samples,
which are not always readily available to the global
research community.
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kins University, Baltimore) who has used an in vitro sys-
tem to identify molecular host-parasite interactions, and
would like to confirm these findings using human sam-
ples, but, like some others, has been unable to obtain
this material thus far. Animal models, therefore, have
been the only alternative to test her hypotheses. A con-
sensus of the attendees was the need for funding to
establish repositories of human samples in conjunction
with carefully collected clinical data, as these would
offer invaluable resources to confirm hypotheses in the
human disease. This lack of access to human samples
often precludes the opportunity to validate findings in
existing animal models, thus their relevance remains
unproven. Closer collaborations between scientists per-
forming human studies and those performing animal
studies are needed to find parallels and differences
between these research approaches, to identify which
models best approximate human infection and disease.
In certain research areas, animal models are clearly
indispensible and are proven tools for discovery. In par-
ticular, many of the anti-malarial drugs currently in use
emerged from small molecules, whose potencies were
assessed in animal models [7]. Historically, drugs were
tested for efficacy against different stages of develop-
ment of rodent parasites, such as Plasmodium berghei,
to identify those drugs that should proceed to testing
against human malaria parasites. Didier Leroy (Medi-
cines for Malaria Venture, Geneva) highlighted recent
advances in which the human malaria parasite Plasmo-
dium falciparum has been propagated in Severe Com-
bined Immunodeficiency mice receiving continuous
injection of human erythrocytes-in other words, an ani-
mal model that incorporates the human parasite [8].
This new approach offers the opportunity to assess drug
efficacy and pharmacokinetics in an in vivo setting
against the true parasite target during its blood stage
development.
Concerns about the applicability of animal models
have been voiced particularly in the areas of disease
pathogenesis, malaria immunity and vaccine testing.
A generally perceived difficulty is the heterogeneity of
malaria presentation in the various mouse-parasite
combinations. The outcomes of infection, as well as the
nature of the immune responses involved in the devel-
opment of disease or the acquisition of immunity, can
differ widely. This has led to questions about which if
any of the mouse models can be extrapolated to under-
stand human disease. Maria Mota (Instituto de Medi-
cina Molecular, Lisbon) emphasized that the spectrum
of malaria in the different models may reflect the diver-
sity of human disease or immunity, and thus should be
considered a strength rather than a limitation [9-13]. In
this view, scientists should use the most appropriate
model for their particular research question rather than
expect one model to represent all facets of human
malaria.
Cerebral malaria in mice is one of the areas of greatest
controversy. Plasmodium berghei ANKA strain causes
accumulations of inflammatory cells and neurological
symptoms leading to death in C57BL/6 mice. One of the
major differences between human cerebral malaria and
the P. berghei ANKA models is thought to be the extent
of parasite sequestration in the brain. In rodents with cer-
ebral malaria this has always been thought to be low,
whereas parasite sequestration in the brain is a character-
istic feature of human cerebral malaria. Numerous cells,
cytokines and chemokines have all been found to play a
role in cerebral malaria in the rodent models, but their
importance in human cerebral malaria is still debated. To
counter these criticisms, some scientists at the meeting
presented evidence of similarities between the animal
models and human disease. Laurent Renia (A*, Singa-
pore) itemized numerous features of both human and
rodent cerebral malaria, and concluded that the two had
significant consistencies. Specific strains of parasites, for
example P. berghei ANKA, do sequester in the rodent
brain, however there is a need to define carefully the
parasite used and how this parasite is produced and
infection initiated. Eleanor Riley showed histological
images (kindly provided by Kevin Couper, LSHTM,
London) documenting accumulations of sequestered
P. berghei ANKA parasites in brains of infected mice.
Importantly it was pointed out that the parasite burden
in the human brain during cerebral malaria can vary
widely between individuals, and in some cases can be
relatively low despite the severe syndrome.
John Harty (University of Iowa) noted that much of
what is known at a basic level of immunology emerged
from studies of infectious diseases in mice, and that
most of this knowledge is applicable to humans despite
minor differences in pathways, receptors and cytokines/
chemokines. Eleanor Riley pointed out the concordance
between immune regulatory mechanisms in humans and
mice, and cited an example of IL-10 production from
IFNg-CD4 T cells being first observed in humans reco-
vering from P. falciparum malaria, and their regulatory
role subsequently being verified in a mouse model. On a
practical level, the mouse malaria models may have not
always predicted the vaccines that would succeed in
humans, however they have always reliably predicted the
vaccine failures, thus preventing further development of
ineffective vaccines. One possible approach for improv-
ing rodent models for dissecting human immune
responses may be the use of humanized mice and/or
chimaeric rodent parasites carrying an introduced gene
from human malaria parasites. However in the view of
several scientists attending the symposium their
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clear, aside from the possibility that human hepatocytes
and erythrocytes in rodents will allow the growth of
human malaria parasites.
Primate malarias were cited as alternative models for
humans and examples of useful models were reviewed.
Mary Galinski (Yerkes National Primate Research Cen-
ter, Emory University, Atlanta) discussed the importance
of several non-human primate malaria models. She
emphasized that many of the key human malaria syn-
dromes and research problems have excellent primate
models that are underutilized, and that increased
resources and collaborations with investigators asking
clinically relevant questions could resolve this problem.
Erica Pasini (BPRC, The Netherlands) described Plasmo-
dium coatneyi in the rhesus monkey as a model of para-
sitized red cell sequestration, while Plasmodium
knowlesi in non-human primates can serve as model for
P. knowlesi human infections in South East Asia, some
of which are characterized by extreme severity [14,15].
Also Plasmodium cynomolgi is closely related and
mimics the unique biology and pathogenesis of Plasmo-
dium vivax. This species offers opportunities to study
the dormant relapsing parasite forms called hypnozoites,
and the unique infected red blood cell features of
P. vivax, to help identify drug and vaccine targets. Plas-
modium knowlesi, also found in humans, has tradition-
ally provided knowledge on merozoite invasion and
antigenic variation. Galinski highlighted the critical need
for sequencing the genomes of these primate malaria
parasites, with closure to enable gene expression studies,
and the possibility that these valuable models might be
lost unless young scientists are supported to gain exper-
tise utilizing these non-human primate resources.
Over-interpretation of data, particularly with respect
to therapeutic intervention, has prompted further skepti-
cism toward experimental models. In mouse models,
inhibiting or blocking cells, cytokines and immune path-
ways, often promoted as potential therapies, are carried
out before onset of symptoms. Whilst these are valid
approaches to dissect mechanisms of pathogenesis, they
are not useful guides for treating human severe disease,
where intervention usually is initiated only after onset of
symptoms. Thus many adjunctive therapies for severe
malaria that have been effective in mice have failed in
human studies. Treatments of infected animals therefore
need to parallel more appropriately the manner in
which treatment is given to humans, and should be
assessed for efficacy when started after the appearance
of clinical signs. In addition, delivering adjunctive treat-
ments in conjunction with other standard anti-malarial
therapies, such as quinine, would better model therapy
delivered to humans.
The consensus of the Keystone attendees coalesced
around the need to reconcile the opposing views of “no
animal model replicates human malaria”,a n d“animal
models are always useful, or are the only approach pos-
sible to dissect mechanisms of immunity or immuno-
pathology”, in order to move research forward. Pierre
Buffet (Paris) suggested that models should be selected
that best reflect the particular human syndrome or
response, and that similarities, differences and limita-
tions of each model should always be described for each
proposed application. Immune mechanisms and pro-
cesses are more likely to have relevance for human
malaria if they are verified in different experimental sys-
tems, with consistencies between several models, from
mouse to primate. Proposed therapies should be exam-
ined when given after a syndrome has developed, and
e f f o r t ss h o u l db em a d et oe x a m i n et h e s et h e r a p i e si n
conjunction with other interventions typically given to
treat humans with malaria.
Conclusions
Experimental and human studies must be closely linked
so that they each inform the other. To this end, bringing
together scientists who study human malaria with those
who study experimental models to compare and con-
trast the details of each might be especially fruitful.
These discussions can identify the areas where the mod-
els are currently known to be useful, and the areas for
further study that might identify where the models are
or are not appropriate.
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